Table 1

Characteristics of participants included in the study

BPH (n = 6)

OCPCa (n = 6)

EPCa (n = 6)

P


Age (years)

67.4 ± 3.9

59.4 ± 2.9

66.9 ± 2.3

0.140a

BMI (kg/m2)

26.5 ± 1.5

25.2 ± 1.3

26.5 ± 1.6

0.783a

Serum total PSA (ng/mL)

8.9 ± 4.7

6.7 ± 1.6

14.7 ± 3.0

0.114b

Prostate weight (g)

107.0 ± 12.9

40.8 ± 4.2

71.2 ± 9.5

0.001a, c

Serum leptin (mg/mL)

3.7 ± 1.0

7.1 ± 2.5

4.9 ± 1.8

0.453a

Combined Gleason score

≤7 (3+4), n (%)

---

5 (83%)

4 (67%)

1.000d

≥7 (4+3), n (%)

---

1 (17%)

2 (33%)


Continuous variables are presented as mean ± SE. aANOVA for independent measures; bKruskal-Wallis test; cLSD post-hoc analysis: BPH versus organ confined PCa, P <0.0001, BPH versus extra prostatic cancer, P = 0.018, extra prostatic cancer versus organ confined PCa, P = 0.040; dFisher exact test. Median (interquartile range) values for serum total PSA: BPH, 4.7 (3.7 to 18.4) ng/mL; organ confined cancer, 5.1 (4.1 to 10.2) ng/mL; extra-prostatic cancer, 14.7 (8.3 to 21.2) ng/mL. ANOVA, analysis of variance; BMI, body mass index; BPH, benign prostatic hyperplasia; EPCa, extra prostatic cancer; OCPCa, organ confined prostate cancer; PCa, prostate cancer; PSA, prostate specific antigen.

Ribeiro et al. BMC Medicine 2012 10:108   doi:10.1186/1741-7015-10-108

Open Data